Results
Lumateperone was well tolerated with a favorable safety profile. There were no clinically relevant changes in extrapyramidal side effect assessments. Mean body weight decreased from SOC antipsychotic baseline with long-term lumateperone treatment. Lumateperone also demonstrated a favorable cardiometabolic and endocrine safety profile.
Symptoms of schizophrenia generally remained stable or improved as measured by PANSS and CGI-S.
Discussion
Lumateperone represents a novel approach to the treatment of schizophrenia with a favorable safety profile in clinical trials. The lack of metabolic, motor and cardiovascular safety issues presents a safety profile differentiated from SOC antipsychotic therapy. These data, taken together, are consistent with and extend data previously reported in placebo-controlled studies in patients with acute schizophrenia with lumateperone and short-term evaluation of lumateperone’s safety.
2 Likes
@ablue
This one mentions weight, thought you might be interested per your previous comment on another ITI-007 post.
It says mean body weight decreased.
3 Likes
Nice thank you. I need a med that doesn’t make me gain weight.
3 Likes
Man if I could lose 60-80 lbs on this I would look normal like I used to and be so damn happy and healthy.
2 Likes
It does look good doesn’t it?
If it turns out to be as safe as they say, and have about the same level of efficacy as other APs, it will be the new standard.
1 Like